Non-invasive PGT (niPGT) examines DNA released into embryo culture media instead of taking a biopsy. This article reviews reported pregnancy and live birth findings alongside PGT-A studies stratified by age and ovarian reserve. Differences in study design and patient groups matter; the findings should not be read as showing that one testing approach benefits every IVF patient.
- Non-invasive PGT: Early comparative findings do not establish equivalence to biopsy-based testing.
- HFEA Analysis of 110,403 Cycles: Associations with live birth were stronger at older maternal ages (RR 1.43 at <35 vs. RR 4.70 at ≥ 40)
- The POSEIDON Group 4 Paradox (n = 54,122): In women ≥ 35 with low ovarian reserve, PGT-A was associated with lower miscarriage rates but no statistically significant difference in per-retrieval live birth rates (RR 0.89)
- Selection Tool vs. Attrition Barrier: In low-yield cohorts, extended culture and biopsy risk resulting in “zero transferable embryos”
Preimplantation Genetic Testing for Aneuploidy (PGT-A) has historically relied on invasive trophectoderm (TE) biopsy, extracting 5 to 10 cells from a Day 5–6 blastocyst. However, reproductive medicine is approaching a dual turning point: the emergence of non-invasive cell-free DNA profiling (niPGT) and a fundamental shift from asking “Does PGT-A work?” to “Which specific patient phenotype actually benefits from it?”
These ESHRE 2026 conference abstracts examine different populations and methods. They suggest that reported PGT-A outcomes vary across patient groups, but observational findings do not establish universal clinical benefit.
How non-invasive PGT analyzes DNA in embryo culture media
The most notable technological transition is the progress of niPGT, which assays embryonic cell-free DNA (cfDNA) released into the micro-droplet culture medium during in vitro growth, avoiding removal of trophectoderm cells:
- One Cohort Within the 2026 Review: In women aged 35–40, niPGT was associated with higher cumulative live birth rates (OR 2.10) and clinical pregnancy rates (OR 1.75) compared to standard morphological grading alone.
- No Significant Difference in One Cohort: No statistically significant difference in cumulative live birth was observed between niPGT and conventional trophectoderm biopsy PGT-A within the primary comparative prospective cohort.
| Parameter | Conventional PGT-A (TE Biopsy) | Non-Invasive PGT (niPGT) |
| Biopsy Method | Laser excision of 5–10 trophectoderm cells | Aspiration of spent culture medium droplet |
| Embryo Trauma | Minimal to moderate (biopsy-dependent) | No trophectoderm biopsy; overall safety not established |
| DNA Source | Trophectoderm nuclear DNA | Cell-free DNA (apoptotic ICM & TE cells) |
| Technical Hurdles | Trophectoderm-ICM mosaicism discordance | Maternal cumulus cell DNA contamination; low DNA yield |
| Clinical Status | Clinically available; not recommended routinely for all IVF patients | Investigational; stronger evidence needed before routine adoption |
The review included eight heterogeneous studies; only one cohort supported comparative estimates. No pooled meta-analysis was feasible. Randomized evidence is needed before routine clinical adoption.
While maternal cumulus cell DNA contamination and ploidy discordance remain technical challenges requiring strict laboratory standardization, niPGT represents an active shift toward biopsy-free genetic screening under investigation.
PGT-A and maternal age: findings from 110,403 HFEA cycles
A 2026 target trial emulation analyzing 110,403 IVF/ICSI cycles from the UK Human Fertilisation and Embryology Authority (HFEA) registry demonstrated a strong age-dependent divergence in PGT-A outcomes:
- Overall Cohort: PGT-A was associated with an elevated Relative Risk (RR) for clinical pregnancy (RR 1.64) and live birth (RR 1.71).
- Age-Stratified Escalation in Live Birth Rate:
- Age <35: RR 1.43
- Age ≥ 35: RR 2.19
- Age ≥ 38: RR 3.18
- Age ≥ 40: RR 4.70
The registry analysis found stronger associations at older ages, but residual confounding prevents a causal interpretation. It did not establish proportional benefit or shorter time to pregnancy.
Low ovarian reserve: reported outcomes in POSEIDON Group 4
The critical clinical boundary appears in patients presenting with combined advanced maternal age and diminished ovarian reserve (low AMH / low AFC)—classified as POSEIDON Group 4.
A propensity score-matched analysis of 54,122 POSEIDON Group 4 patients revealed clear limitations:
- Miscarriage Findings: The PGT-A group had a lower miscarriage rate in this retrospective comparison; the study cannot establish causation.
- No Improvement in Live Birth: Neither the per-transfer nor the per-oocyte-retrieval live birth rate improved (RR 0.89; no statistically significant difference).
This highlights a fundamental biological principle: PGT-A is an exclusionary selection tool, not a therapeutic agent. It cannot repair an aneuploid embryo or convert an abnormal cell line into a normal one.
- With multiple blastocysts: PGT-A may help prioritize embryos, but does not guarantee implantation or eliminate miscarriage.
- With very few embryos: Testing may leave no embryo considered suitable for transfer. The cited study did not establish that Day-3 or untested transfer is superior.
PGT-A selection: age, ovarian reserve and blastocyst yield
The decision to utilize PGT-A requires personalized stratification across three biological axes:
Maternal age + ovarian reserve + available embryos
|
Individualized counseling about PGT-A
Consider benefits, limitations and transfer opportunities
niPGT remains investigational
- Individualized discussion: PGT-A decisions may consider age, embryo yield and reproductive history. Known structural rearrangements raise a separate PGT-SR question for genetic counseling.
- Low embryo yield: For POSEIDON Group 4 patients, counseling should address the possibility of no embryo being available for transfer and the uncertainty in live birth benefit.
Interpreting the evidence for individualized embryo testing
PGT-A is neither a universal requirement for all IVF cycles nor an unhelpful add-on. Its value is defined by the patient’s biological profile.
PGT-A may help select embryos in some patients, but universal live birth benefit is unproven. niPGT remains investigational. With low embryo yield, possible loss of transfer opportunities needs careful discussion.
For related evidence with different clinical questions and endpoints, read about PGT-A outcomes per transfer versus per retrieval and mosaic embryo transfer and PGT-A interpretation.
Medical Sources & Conference Proceedings
- Journal: Human Reproduction (ESHRE 2026 Annual Meeting Supplement, July 2026)
- Studies Included:
※ This article was synthesized based on clinical studies presented at the 2026 ESHRE Annual Meeting and published in the Human Reproduction supplement, alongside practice guidelines from the ASRM and ESHRE. It does not replace individualized clinical diagnosis or medical care, and specific treatment decisions should always be made in consultation with a qualified reproductive endocrinologist.
※ The images associated with this article were generated using generative AI (ChatGPT, OpenAI) as illustrative visual references and do not depict real individuals.